Harmony Biosciences : HRMY Q1 2022 Financial and Business Update - FINAL.pdf

Legal Disclaimer

This presentation includes forward‐looking statements within the meaning of the Private Securities Reform Act of

1995. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding Harmony Biosciences Holdings, Inc.'s (the "Company") future financial position, business

strategy and plans and objectives of management for future operations, should be considered forward-looking statements. Forward-looking statements use words like "believes," "plans," "expects," "intends," "will," "would," "anticipates," "estimates," and similar words or expressions in discussions of the Company's future operations, financial performance or the Company's strategies. These statements are based on current expectations or objectives that are inherently uncertain, especially in light of the Company's limited operating history. These and other important factors discussed under the caption "Risk Factors" in the Company's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 28, 2022 and its other filings with

the SEC could cause actual results to differ materially and adversely from those indicated by the forward-looking statements made in this presentation. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change.

This presentation includes information related to market opportunity as well as cost and other estimates obtained from internal analyses and external sources. The internal analyses are based upon management's understanding of

market and industry conditions and have not been verified by independent sources. Similarly, the externally sourced information has been obtained from sources the Company believes to be reliable, but the accuracy and completeness of such information cannot be assured. Neither the company, nor any of its respective officers, directors, managers, employees, agents, or representatives, (i) make any representations or warranties, express or implied, with respect to any of the information contained herein, including the accuracy or completeness of this presentation or any other written or oral information made available to any interested party or its advisor (and any liability therefore is expressly disclaimed), (ii) have any liability from the use of the information, including with respect to any forward-looking statements, or (iii) undertake to update any of the information contained herein or provide additional information as a result of new information or future events or developments.

Harmony's Strategy for Growth

Q1 2022 WAKIX® Net Revenue Performance

Q1 2022 Net Revenue of $85.3M

1Q21	4Q21	1Q22	∆ 1Q22 vs. 4Q21	∆ 1Q22 vs. 1Q21
$59.7	$91.2	$85.3	(6%)	43%

• ▪ 43% growth Q1 2022 vs. Q1 2021

• ▪ Surpassed $500M in cumulative net revenue - achieved in less than 2 ½ years since launch

Driving Growth Through Our Launch For WAKIX Q1 2022 Performance